Form 8-K - Current report:
SEC Accession No. 0000950170-24-087276
Filing Date
2024-07-29
Accepted
2024-07-29 16:04:59
Documents
13
Period of Report
2024-07-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240725.htm   iXBRL 8-K 58684
2 EX-99.1 awh-ex99_1.htm EX-99.1 16790
3 GRAPHIC img245972787_0.jpg GRAPHIC 933834
  Complete submission text file 0000950170-24-087276.txt   1475257

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT awh-20240725.xsd EX-101.SCH 32088
15 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240725_htm.xml XML 4903
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241152290
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)